Saeed Shaikh, MD
Interventional Cardiology · Indianapolis, INNPI 1407828817
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.8%), food and beverage and grants — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Edwards Lifesciences at 35.2% of the total. Reporting peaked in 2019 at $4,665 and has fallen 66.4% since, to $1,566 in 2025.
Across 183 payments — averaging $76.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$5K
- Abbott$4K
- Boston Scientific$2K
- Medtronic$2K
- Livanova USA, Inc.$876
- Novartis$161
- plus $678 from 11 others
Across 107 payments — averaging $3287.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$132K
- CSL Behring$115K
- Novartis$44K
- Abbott$39K
- Amgen$22K
What the payments were for
- Grants$891%
- Travel & lodging$8,17759%
- Food & beverage$5,64441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 57 | $4,889 |
| Abbott | 56 | $3,799 |
| Boston Scientific | 29 | $1,957 |
| Medtronic(2 entities) | 15 | $1,549 |
| Livanova USA, Inc. | 1 | $876 |
| Novartis | 7 | $161 |
| Abiomed | 2 | $144 |
| Johnson & Johnson | 1 | $125 |
| Bard Peripheral Vascular, Inc. | 1 | $118 |
| Medical Device Business Services, Inc. | 2 | $59 |
| AstraZeneca | 3 | $55 |
| Pfizer | 3 | $52 |
| Terumo Medical Corporation | 1 | $39 |
| Biosense Webster, Inc. | 2 | $29 |
| Amgen | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$1,388
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,248
- TRICLIP$1,138
- CoreValve Evolut$1,136
- MitraClip$1,106
- Tandem Life Kit$876
- GENERAL - THERAPIES$815
- WATCHMAN Access System$205
- SAPIEN 3 Ultra RESILIA$179
- Impella$125
- XARELTO$125
- COREVALVE EVOLUT R$124
- Watchman$102
How this compares
$13,909 in reported general payments places this provider in the 70th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 104 | $126,392 |
| Repatha SureclickEvolocumab | 34 | $49,298 |
| EntrestoSacubitril/Valsartan | 15 | $24,623 |
| XareltoRivaroxaban | 16 | $18,254 |
| VascepaIcosapent Ethyl | 14 | $9,928 |
| Metoprolol Succinate | 293 | $4,416 |
| Atorvastatin Calcium | 296 | $3,126 |
| ClopidogrelClopidogrel Bisulfate | 203 | $2,683 |
| Ezetimibe | 103 | $2,569 |
| Carvedilol | 286 | $2,087 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 45 | $1,825 |
| Rosuvastatin Calcium | 130 | $1,329 |
| Losartan Potassium | 113 | $1,286 |
| Potassium Chloride | 40 | $847 |
| Nitroglycerin | 56 | $789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52 | $126,392104 claims |
| NovartisEntresto | $161 | $24,62315 claims |
| Johnson & JohnsonXarelto | $125 | $18,25416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Indianapolis
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Michael BallIndianapolis$76K
- Anjan SinhaIndianapolis$54K
- Nitesh GadeelaIndianapolis$48K
- George RevtyakIndianapolis$45K
- Scott SharpIndianapolis$41K
- Amrish MalhiIndianapolis$37K
- Jeffrey BreallIndianapolis$21K
- Sandeep DubeIndianapolis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.